期刊文献+

他莫昔酚对耐药细胞系K562/DOX多药耐药逆转作用的研究 被引量:2

Study on the reversing effect of tamoxifen on multidrug resistant cell line K562/DOX
下载PDF
导出
摘要 目的:寻找有效的多药耐药逆转剂。方法:以他莫昔酚作为耐药逆转剂,用[溴化-3(4,5-二甲基-2-噻唑基)-2,5-二苯基四唑氮]MTT法体外药物敏感试验,观察他莫昔酚对多药耐药白血病细胞株K562/DOX的药物敏感性的影响。结果:他莫昔酚可增强阿霉素(DOX)对K562/DOX的细胞毒作用,对K562细胞无影响。结论:他莫昔酚是一种有效的多药耐药逆转剂。 OBJECTIVE:To develop effect of tamoxifen on resistance modulators. METHODS: The effects of tamoxifen on drug sensitivity in multidrug resistant human leukemic cell line K562/DOX were studied by MTT corlori- metric assay. RESULTS:Tamoxifen enhanced the cytotoxicity of doxorubicin (DOX) to K562/DOX and had no effect on efflux of DOX in K562 cells. CONCLUSION: Tamoxifen is an effective reversal agent of multidrug resistance.
机构地区 解放军第
出处 《药学实践杂志》 CAS 2001年第5期264-265,共2页 Journal of Pharmaceutical Practice
关键词 他莫昔酚 药物耐受性 耐药逆转剂 抗癌药 tamoxifen trug tolerance effective reversal agent
  • 相关文献

参考文献2

共引文献13

同被引文献36

  • 1李凤云,张永恒,于桂兰,吴玉波,孙世忠.十全大补冲剂对肿瘤化疗药物增效减毒作用的研究[J].肿瘤,1996,16(1):38-40. 被引量:25
  • 2李惠芳,孙桂香,卢薇薇,于载泺.多药耐药基因反义寡核苷酸逆转肿瘤细胞耐药的初步研究[J].中华血液学杂志,1997,18(2):76-79. 被引量:10
  • 3高烨.高晓东.吴芳颐.蟾酥灵对HL-60/ADR耐药细胞株作用的初步研究[J].中国实验血液学杂志,2001,9:173-173.
  • 4Tai HL. Technology evaluation: Valspodar, Novartis[J]. Curt Opin Mol Ther, 2000,2(4):459-467.
  • 5Marbeuf Gueye C, Salerno M, Quidu P, et al. Inhibition of the Pglycoprotein and multidrug resistance protein - mediated efflux of anthracyclines and calceina cetoxymethyl ester by PAK-104P[J]. Eur J Pharmacol, 2000,391(3):207-216.
  • 6Motoji T, Motomura S, Wang YH. Multidrug resistance of acute leukemia and a strategy to overcome it[J].Int J Hematol, 2000, 72(4):418-424.
  • 7Swannie HC, Kaye SB. Protein kinase C inhibitors[J]. Curr Oncol Rep, 2002, 4(1):37-46.
  • 8Komuro Y, Udagawa Y, Susumu N, et al. Paclitaxel and SN-38 overcome cisplatin resistance of cell lines by down - regulating the influx and efflux system of cispaltin[J]. Cancer Res, 2001,92(11):1242-1250.
  • 9Poirson Biochat F, Concalves RA, Miceoli L, et al. The expression of drug resistance gene products during the progression of human prostate cancer[J]. Clin Cancer Res, 2000,6(2):643-653.
  • 10Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo characterization of XRl1576, a novel, orally active, dual inhibitor of topoisomeraseⅠand Ⅱ[J]. Anticancer Drugs, 2002, 13(1):15-28.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部